Related Experiment Video
Updated: Apr 5, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Novel adjuvant therapies for pancreatic adenocarcinoma
Tolutope Oyasiji1, Wen Wee Ma1
11 Department of Surgical Oncology, 2 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Abstract:
Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.
Related Concept Videos
Tumor Immunotherapy
Chronic Pancreatitis II: Collaborative Care
Assessment:
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies

